{"id":205736,"date":"2017-07-15T22:44:41","date_gmt":"2017-07-16T02:44:41","guid":{"rendered":"http:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/post-marketing-data-reinforce-sustained-efficacy-and-safety-of-cosentyx-in-psoriasis-the-pharma-letter-registration\/"},"modified":"2017-07-15T22:44:41","modified_gmt":"2017-07-16T02:44:41","slug":"post-marketing-data-reinforce-sustained-efficacy-and-safety-of-cosentyx-in-psoriasis-the-pharma-letter-registration","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/transhuman-news-blog\/psoriasis\/post-marketing-data-reinforce-sustained-efficacy-and-safety-of-cosentyx-in-psoriasis-the-pharma-letter-registration\/","title":{"rendered":"Post-marketing data reinforce sustained efficacy and safety of Cosentyx in psoriasis &#8211; The Pharma Letter (registration)"},"content":{"rendered":"<p><p>      Positive five year efficacy and safety results for Cosentyx      (secukinumab) from a Phase III long-term    <\/p>\n<p>      To continue reading this article and to access exclusive      features, interviews, round-ups and commentary from the      sharpest minds in the pharmaceutical and biotechnology space      you need to be logged into the site and have an active subscription or trial      subscription. Please loginorsubscribe in order to continue reading.      Claim a week's trial      subscriptionby signing up for free today and      receive our daily pharma and biotech news bulletin free of      charge, forever.    <\/p>\n<p>    BiotechnologyCosentyxDermatologicalsDrug TrialImmunologicalsNovartisPsoriasisResearchSwitzerlandVasant Narasimhan  <\/p>\n<p>            Access The Pharma Letter's latest news free for 7 days          <\/p>\n<\/p>\n<p>          PLUS... you can receive the Pharma Letter headlines and          news roundup email free forever        <\/p>\n<p>          Click here to          take a free trial        <\/p>\n<p>            Unlimited access to The Pharma Letter site for a whole            year            Only 77 per month or 820 per year          <\/p>\n<\/p>\n<p>          Click here to          subscribe        <\/p>\n<p><!-- Auto Generated --><\/p>\n<p>Visit link:<br \/>\n<a target=\"_blank\" href=\"https:\/\/www.thepharmaletter.com\/article\/post-marketing-data-reinforce-sustained-efficacy-and-safety-of-cosentyx-in-psoriasis\" title=\"Post-marketing data reinforce sustained efficacy and safety of Cosentyx in psoriasis - The Pharma Letter (registration)\">Post-marketing data reinforce sustained efficacy and safety of Cosentyx in psoriasis - The Pharma Letter (registration)<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p> Positive five year efficacy and safety results for Cosentyx (secukinumab) from a Phase III long-term To continue reading this article and to access exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space you need to be logged into the site and have an active subscription or trial subscription. Please loginorsubscribe in order to continue reading. Claim a week's trial subscriptionby signing up for free today and receive our daily pharma and biotech news bulletin free of charge, forever.  <a href=\"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/transhuman-news-blog\/psoriasis\/post-marketing-data-reinforce-sustained-efficacy-and-safety-of-cosentyx-in-psoriasis-the-pharma-letter-registration\/\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[22],"tags":[],"class_list":["post-205736","post","type-post","status-publish","format-standard","hentry","category-psoriasis"],"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/posts\/205736"}],"collection":[{"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/comments?post=205736"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/posts\/205736\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/media?parent=205736"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/categories?post=205736"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/tags?post=205736"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}